Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSD17B4 | P51659 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27478488 | 0.80 | KMT2A (0.45) | KMT2AFFAR4HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL12205445 | 0.76 | KMT2A (0.46) | KMT2AFFAR4HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL11732024 | 0.74 | MAOA (0.68) | KMT2AFFAR4HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL8184983 | 0.73 | TP53 (0.52) | KMT2AHSD17B1HSD17B2ALDH1A1ALDH2 | |
| SCHEMBL27818365 | 0.72 | NPSR1 (0.47) | KMT2AFFAR4HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL24402162 | 0.72 | GAA (0.56) | KMT2AFFAR4HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL12205458 | 0.72 | KMT2A (0.43) | KMT2AFFAR4HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL27551857 | 0.71 | KMT2A (0.51) | KMT2AFFAR4TP53MAPTNPSR1 | |
| SCHEMBL11832388 | 0.70 | KMT2A (0.53) | KMT2AFFAR4HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL12437778 | 0.69 | HTR2A (0.63) | KMT2AFFAR4HSD17B1HSD17B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858923-B2 | Secondary amine-substituted coumarin compounds and their uses as fluorescent labels | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-01-02 | — | — | US | disclosed |
| US-20230025669-A1 | SECONDARY AMINE-SUBSTITUTED COUMARIN COMPOUNDS AND THEIR USES AS FLUORESCENT LABELS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858923-B2 | Secondary amine-substituted coumarin compounds and their uses as fluorescent labels | FBL, NSUN2, DNA2 | KMT2A 905/4885FFAR4 4332/4885HSD17B1 3610/4885 |
| US-20230025669-A1 | SECONDARY AMINE-SUBSTITUTED COUMARIN COMPOUNDS AND THEIR USES AS FLUORESCENT LABELS | FBL, NSUN2, DNA2 | KMT2A 905/4885FFAR4 4332/4885HSD17B1 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.